Literature DB >> 20927502

Serial NT-proBNP measurements for risk stratification of patients with decompensated heart failure.

C Lüers1, A Schmidt, R Wachter, F Fritzsche, A Sutcliffe, S Kleta, A Zapf, G Hagenah, L Binder, B Maisch, B Pieske.   

Abstract

PURPOSE: NT-proBNP is an important prognostic predictor in patients with heart failure. However, it is unknown whether a change of NT-proBNP plasma levels in the early phase of decompensation might be of additional prognostic value in patients with acute decompensation of heart failure. METHODS AND
RESULTS: NT-proBNP plasma levels of 116 patients with decompensated heart failure from ischemic/non-ischemic origin were measured at baseline and at 12, 24 and 48 h after hospital admission. Baseline levels and changes of plasma levels within the first 48 h were correlated with 30-day mortality. In all patients, NT-proBNP 12 h after admission was highest and superior with respect to the prediction of 30-day mortality compared to plasma levels on admission. In total, 38 patients died within the first 30 days. In these patients absolute NT-proBNP plasma levels were significantly higher and the increase within 12 h after admission was more pronounced compared to survivors (p<0.001). NT-proBNP at 12 h after admission also had the highest predictive value for the 30-day mortality rate in patients with acute myocardial infarction. The increase of NT-proBNP plasma levels within 12 h after admission had the highest predictive value in patients suffering from decompensated heart failure.
CONCLUSIONS: NT-proBNP is a powerful marker of 30-day mortality in patients with decompensated heart failure of ischemic and non-ischemic origin. Compared with single baseline measurements, serial measurements of NT-proBNP plasma levels within 12 h after hospital admission may be used to increase the predictive value of NT-proBNP with regard to the early identification of patients who are at high risk of mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927502     DOI: 10.1007/s00059-010-3377-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  30 in total

1.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

2.  Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: results from the SHOCK trial.

Authors:  Harvey D White; Sebastian T Palmeri; Lynn A Sleeper; John K French; Cheuk-Kit Wong; April M Lowe; Julia W Crapo; Patrick T Koller; Kenneth W Baran; Jean L Boland; Judith S Hochman; Galen S Wagner
Journal:  Am Heart J       Date:  2004-11       Impact factor: 4.749

3.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.

Authors:  A M Richards; R Doughty; M G Nicholls; S MacMahon; N Sharpe; J Murphy; E A Espiner; C Frampton; T G Yandle
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

4.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study.

Authors:  R Kazanegra; V Cheng; A Garcia; P Krishnaswamy; N Gardetto; P Clopton; A Maisel
Journal:  J Card Fail       Date:  2001-03       Impact factor: 5.712

5.  Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock.

Authors:  Toshiro Katayama; Hiroshi Nakashima; Chisa Takagi; Yukiharu Honda; Shin Suzuki; Katsusuke Yano
Journal:  Circ J       Date:  2005-01       Impact factor: 2.993

6.  N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Christian W Hamm; Veselin Mitrovic; Nicte-Ha Lantelme; Harvey D White
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

7.  N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

Authors:  Paulo Bettencourt; Ana Azevedo; Joana Pimenta; Fernando Friões; Susana Ferreira; António Ferreira
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

8.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.

Authors:  F D R Hobbs; R C Davis; A K Roalfe; R Hare; M K Davies; J E Kenkre
Journal:  BMJ       Date:  2002-06-22

9.  Prognostic importance of increased plasma amino-terminal pro-brain natriuretic peptide levels in a large noncardiac, general intensive care unit population.

Authors:  Anastasia Kotanidou; Petros Karsaliakos; Marinella Tzanela; Irini Mavrou; Petros Kopterides; Evangelos Papadomichelakis; Maria Theodorakopoulou; Efi Botoula; Iraklis Tsangaris; Michalis Lignos; Ignatios Ikonomidis; Ioannis Ilias; Apostolos Armaganidis; Stylianos E Orfanos; Ioanna Dimopoulou
Journal:  Shock       Date:  2009-04       Impact factor: 3.454

Review 10.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

View more
  7 in total

1.  Neuregulin in heart failure : reverse translation from cancer cardiotoxicity to new heart failure therapy.

Authors:  C A Geisberg; D J Lenihan
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

2.  Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.

Authors:  D Cardinale; C M Cipolla
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 3.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

4.  NT-proBNP as Marker of Ventricular Dilatation and Pulmonary Regurgitation After Surgical Correction of Tetralogy of Fallot: A MRI Validation Study.

Authors:  Annalisa Paolino; Tarique Hussain; Antonio Pavon; Maria Nieves Velasco; Sergio Uribe; Antonio Ordoñez; Israel Valverde
Journal:  Pediatr Cardiol       Date:  2016-11-21       Impact factor: 1.655

5.  Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy?

Authors:  Jennifer Franke; Lutz Frankenstein; Dieter Schellberg; Amer Bajrovic; Jan Sebastian Wolter; Philipp Ehlermann; Andreas O Doesch; Manfred Nelles; Hugo A Katus; Christian Zugck
Journal:  Clin Res Cardiol       Date:  2011-07-16       Impact factor: 5.460

6.  Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain.

Authors:  M Valenti; D Viganò; M G Casico; T Rubino; L Steardo; D Parolaro; V Di Marzo
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

7.  Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome.

Authors:  Marijke van der Meulen; Susanna den Boer; Gideon J du Marchie Sarvaas; Nico Blom; Arend D J Ten Harkel; Hans M P J Breur; Lukas A J Rammeloo; Ronald Tanke; Ad J J C Bogers; Willem A Helbing; Eric Boersma; Michiel Dalinghaus
Journal:  ESC Heart Fail       Date:  2021-02-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.